Thermo Fisher Scientific (NYSE:TMO) COO Gianluca Pettiti Sells 400 Shares

Thermo Fisher Scientific Inc. (NYSE:TMO) COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gianluca Pettiti also recently made the following trade(s):

• On Monday, February 9th, Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $466.04 on Thursday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99. The company’s 50 day moving average is $496.82 and its 200 day moving average is $548.19. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company has a market cap of $173.19 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 2.07 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter in the prior year, the company earned $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.83 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is 10.34%.

Analysts Set New Price Targets

Several research analysts have recently commented on TMO shares. Evercore reiterated an “outperform” rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Monday, January 5th. TD Cowen cut their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. Citigroup raised their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average price target of $623.05.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors have recently bought and sold shares of the company. Howard Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after buying an additional 16 shares during the period. Petros Family Wealth LLC lifted its stake in Thermo Fisher Scientific by 3.9% during the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock worth $264,000 after purchasing an additional 17 shares during the last quarter. Salomon & Ludwin LLC lifted its stake in Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after buying an additional 17 shares during the last quarter. Financial Management Network Inc. grew its holdings in Thermo Fisher Scientific by 3.7% during the third quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock worth $248,000 after acquiring an additional 18 shares during the period. Finally, Pallas Capital Advisors LLC grew its holdings in Thermo Fisher Scientific by 1.5% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock worth $728,000 after acquiring an additional 18 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.